Introduction
The Glycemia Modeling Working Group (GMWG) was originally formed in 2008 with the intent to document current practices in metabolic modeling for advancing closed-loop glucose control. The intent was to formulate a framework for the exchange of information and collaboration among research centers, to identify limitations of glycemia models, and to identify essential tasks that need to be accomplished in order to achieve a fully automated closed-loop glucose control system. The working group, which was then composed of 25 scientists representing many of the world leaders in glycemia modeling, was reconvened in 2009 with 39 scientists in attendance, including 14 of the original 25 participants. This report serves to update the progress achieved on the 2008 recommendations 1 and summarizes the topics discussed in the 2009 meeting. As with the 2008 report, we sought to document the collective efforts and view points of the world leaders in glycemia modeling, to increase awareness of the existing modeling challenges and opportunities, and to provide information to guide funding priorities and future solicitations.
Progress Achieved on the 2008 Recommendations
Briefly, the main conclusions and recommendations from the 2008 GMWG meeting were as follows: 1 1. Physiological variance represents the single largest technical challenge to creating accurate simulation models.
2. A Web site describing the different models and data supporting them should be made publicly available, with funding agencies and journals requiring investigators to provide open access to both models and data.
3. Existing simulation models should be compared and contrasted using the same evaluation and validation criteria to better assess the state of the art, understand any inherent limitations in the models, and identify gaps in data and/or model capability.
Although it was generally agreed that an accurate description of physiological variances continue to be a major challenge and that models should be made public (see recommendations 1 and 2), modest progress was reported. Data for 30 subjects were made available for a model developed at the University of Virginia 2 (UVA; simulator; contact UVA Patent Foundation for details). The subjects-10 adults, 10 adolescents, and 10 childrenwere selected from a larger virtual population of 300 subjects (100 in each group) with the intent to describe a wide range of subjects, including both "average" and "extreme" subjects (with the extreme subjects used to assess the robustness of different control algorithms 3 ). Finally, intraday variances in parameters characterizing a model developed at Medtronic 4 were also described for 10 subjects (intraday variation in model parameters identified in three 6-hour windows). Nevertheless, given the importance placed on understanding how intrasubject variability might affect closed-loop control and the potential for models to aid in the development of effective control algorithms, these are small steps. Particularly disappointing is that no Web site was created describing the different models (part of recommendation 2), and no publication comparing different modeling approaches or identifying any limitations or gaps has appeared (recommendation 3).
The prevailing view as to why there was so little progress on model comparison was that the derivation and validation of the models, as well as the identification of the underlying parameters, represent a substantial amount of work by the individuals who developed them and that making such information freely available to other investigators or companies was an unrealistic objective. The models, associated simulation software, and any related control algorithms that might be derived from them are viewed as potential sources of revenue through intellectual property royalties and licensing agreements or as providing a competitive edge when applying for extramural funding. At issue is the ability to access individual parameter sets that comprise the average parameter values typically reported in publications. It was widely agreed that simulations performed using the average parameter values do not yield useful results when comparing models or evaluating control algorithms, although they may still serve in a more limited capacity.
by these individuals as 4 mg/dl/min). However, of those that believed the delay is ≤10-15 min, 50% believed that insulin can cause changes in the blood (i.e., plasma)-to-ISF glucose gradient. Also, 50% still indicated that the biggest impediment to the development of an artificial pancreas is the ability to reliably measure glucose. Of the 50% of the respondents who did not believe that glucose sensing is the problem, the predominant sentiment (60% [9/13] of the respondents) was that the absence of a high-fidelity predictive model is the main impediment. Surprisingly, only 4 of 26 respondents believed that a complete understanding of what the control strategy should be remains an open issue. Unfortunately, we did not survey these individuals as to what control strategy they believed should be used; however, given the number of respondents who indicated that the largest impediment was the lack of a high-fidelity predictive model suggests that most would favor some form of model predictive control (MPC).
Arguably, MPC should always be the preferred approach in instances where a model can be shown to reliably predict future values of the controlled variable (glucose). However, in cases where the model is less than perfect, it has been argued 5 that other control strategies may work equally well or better. The ability of a model to predict glucose excursions using meal and insulin information likely depends on the interday and/or intraday variability in the parameters of the model. This is consistent with the conclusion arrived at in the 2008 GMWG meeting 1 that physiological variance represents the single biggest technical challenge to creating accurate simulation models.
In this year's meeting, we attempted to expand on this topic by quantifying the extent of the variance and discussing some of the underlying sources. Intraday variance in insulin sensitivity was thought to effect changes in fasting glucose of >15% in 21 of 23 respondents (91%), with 12 respondents (52%) believing the variability to be ≥30%. To counter these changes, respondents generally believed that basal rates either need to be adjusted by ≥30% (8 of 22 respondents) or somewhere between 15% and 30% (10 of 22 respondents). Exercise was widely believed to be one of the underlying factors responsible for changing insulin requirements, with 78% (18/23) of the respondents believing that exercise affects both the needed insulin amount and acting time (four additional respondents believed the interaction between exercise and model parameters to be more complex than simple changes in insulin magnitude and time of effect). Similarly, the effect of a high-fat meal was perceived to be more complex than putative changes in gastric emptying [6] [7] [8] [9] by more than two-thirds of the respondents, with approximately one-half of the respondents believing that
Although it is becoming clear that individual investigators are unlikely to make their model parameters available, a positive outcome of the meeting was that virtually all the investigators embraced the idea of a subsequent Modeling Comparison Workshop in which different models would be compared and contrasted using common data sets and testing criteria. 1 Also, there was widespread agreement on what we would like to accomplish with the individual models-mainly achieve a better understanding of the strengths and weakness of each model when used to compare and evaluate different control algorithms. There was also substantial agreement on numerous aspects of how the control algorithm should be configured and introduced. We highlight these discussions next and return to the issue of how to compare models in our conclusion.
Specific Topics Discussed at the 2009 Glycemia Modeling Working Group Meeting
Similar to the 2008 GMWG meeting, a series of questions was used to guide the 2009 meeting. The questions and the participants' answers are provided in the Appendix. Not all responses add up to 39, as some participants left some questions blank and the answers from the authors were not tabulated. Some questions sought to survey opinions as to the state of glycemia monitoring, modeling, and control technologies (by definition questions that have no correct or incorrect answer), while other questions attempted to obtain answers that are not necessarily known but that could be easily verified using the different metabolic models. As the questions were largely predetermined by the authors, the following discussion undoubtedly reflects the authors' biases, with the hope that future meetings can mitigate this issue by having participants submit their own questions in advance. With this caveat in mind, the following summarizes the discussions and our analyses of the tabulated results.
Generally, the working group remained cautiously optimistic that glucose sensor technology is advancing, with ~19% (5/27) of the respondents believing that closedloop control can be achieved with today's technology and an additional 41% (11/27) of the respondents believing that improvements in continuous glucose monitoring (CGM) calibration and filter routines will suffice. Approximately 60% of the respondents did not believe that interstitial fluid (ISF) glucose is substantially delayed compared with plasma glucose, but only 30% of the respondents believed that the maximum rate of change of ISF glucose is well characterized (with the average value reported metabolic parameters could be affected for ≥12 h after the meal. Almost 80% of the participants thought that a closed-loop control algorithm should be able to compensate for these changes with little (12 of 25 respondents) or no (7 of 25 respondents) error.
Interestingly, when asked about "insulin sensitivity factors" commonly used in open-loop therapy, there was no consensus whether a bolus is expected to effect a transient or steady state decrease in glucose given that the basal rate is appropriately adjusted to maintain glucose levels at a stable level (specified as 130 mg/dl in question 10). Essentially, the vast majority of respondents (82% [18/22] ) indicated that the effect could not be classified as transient or fixed in all cases (of the 4 respondents who chose one of the two outcomes, the responses were equally divided). What makes the response interesting is that most models predict the response to be transient (KADIS 10,11 being a notable exception; see the discussion in reference 12). This is one of the few model characteristics that can be determined by examining the model equations alone.
If it is true that, after the basal rate is adjusted to achieve stable glucose, administering a bolus of insulin can lead to a steady state decrease in blood glucose in some subjects-whereas in other subjects, the bolus has only a transient effect-then models need to be configured to capture this variability.
One of the more obvious differences among competing metabolic models is their order, which is defined as the number of differential equations used to describe changes in glucose. This was generally acknowledged to be a complex issue. Only 30% (8/26) of the respondents thought that, if open-loop profiles were equally well described by two models with different order, then simulated closed-loop profiles would be close; 65% (17/26) of the respondents indicated that the question could only be answered by an analysis of the different model structures. Observability analysis 13 applied to the linear components of the different models, or to linearized versions of nonlinear components, was discussed as a potential method to assess the need for high-order model terms. [11/26] of the respondents). The PK/PD profiles have been obtained clinically and characterized for virtually all insulin types and mixes, [14] [15] [16] [17] by subject age, 18 and by the number of days of catheter use 19 (pump). One might argue that other key clinical observations should also be reproducible by model simulation. For example, one could ask whether the model's response to a short interruption in insulin delivery should also be similar to the response observed clinically, 20 as an interruption in pump delivery is putatively believed to be a first step in transitioning from open-to closed-loop control and is widely accepted to be critical to the overall safety of closed-loop devices. 21 Obtaining a given model's PK/PD profile, or its response to an interruption in pump insulin delivery, is relatively trivial if the model equations and parameters are known; however, the question remains as to who would do such simulations and how results that differ substantially from those observed in the clinical setting would be perceived, given that many clinical studies are now approved based on model simulations. 2 As with the first GMWG meeting, 1 participants were careful to distinguish between models that are to be used for simulation and models that are to be used for control (see the discussion in the first GMCW report for definitions 1 ). A class of data-driven models was also discussed at this year's meeting, with the primary question being whether the glucose system is stationary. This is an important consideration in establishing the ability of linear autoregressive (AR) models to improve short-term glucose prediction accuracy (i.e., glucose predictions in the 30-60 min window). On this item, the majority of the respondents were of the opinion that glucose signals are either not stationary (14 of 20 respondents) or, at best, weakly stationary (6 of 20 respondents). Generally, stable AR models are only representative of stationary processes, but it may be possible to mitigate the problem by detrending the signal-for example, by computing the difference between two consecutive data points-before developing an AR model. What is "at stake" is the ability to use these models to improve short-term predictions compared with other modeling approaches (e.g., Kalman filter 22 ) or the first-order finite difference methods commonly used in existing CGM products (i.e., predictions based on the assumption that future values can be approximated by the most recent value plus the glucose rate of change times the desired future interval). Model-based approaches have substantial potential to improve hypoglycemic detection rates, although it is interesting to note that 40% of the respondents indicated that there is no real consensus on what constitutes a hypoglycemic event.
As in the first GMWG meeting, 1 there was widespread agreement on what the unanswered modeling questions are but substantially less agreement on how to answer the questions. The model-related questions and/or needs believed to be unanswered or unmet include the following:
1. The need for a mechanism that would allow investigators to simulate different models (see question 14 of the survey).
The key question was how an investigator can validate a model before using it to make informed decisions regarding the choice of a control algorithm, optimal tuning of a given control algorithm, estimating the range of stability for control parameters, and assessing closed-loop stability as subject parameters change.
2. The need for models to include realistic interday and intraday variance in insulin requirements. This variance was generally believed to lead to substantial changes in the required basal rates (questions 6, 7, 10, and 11), with the effect of a high-fat meal and/or prior exercise possibly contributing to the variability (questions 12 and 13). The key question is of how to compare closed-loop simulations performed on models that do not include this variability with clinical studies in which the variability can be substantial.
3. Insulin PK/PD profiles associated with different models were widely thought to be an important model characteristic that could affect how different control algorithms perform (question 15). The key issue again being how to interpret closed-loop simulations on virtual subjects with PK/PD responses that are substantially different from published studies.
4. Continuous glucose monitoring accuracy was believed by at least one-half of the participants (questions 1 and 5) to still be the primary obstacle in achieving closedloop control, with the inherent properties of ISF still needing to be resolved (questions 2 and 9) and the statistical properties of the glucose signal (i.e., mean, variance, and autocorrelation) still needing to be characterized (question 4). The key question was how to evaluate models for their ability to improve predictive alerts that warn subjects of impending hyperglycemic or hypoglycemic conditions (also ill defined; see question 3).
Questions identified at this year's meeting reflect many of the same issues discussed at the 2008 GMWG meeting. The need for investigators to have access to different models was identified at the 2008 meeting as a key recommendation but was generally accepted at this year's meeting to have been unrealistic. The need for models to reflect the variability in insulin requirements commonly observed in clinical practice 23, 24 continues to be an issue. The issue as to whether a simulation model's insulin PK/PD profile needs to be similar to measured profiles [14] [15] [16] [17] [18] [19] was a new argument this year, but it can be seen as a simple example of why individual investigators seek access to model parameters. The profile was widely viewed as an important consideration for designing a closed-loop algorithm (as also true for an open-loop algorithm). The PK/PD profiles can now be simulated for a limited set of patients identified with the Cambridge simulator, 3 as the developer of that model allows access to individual parameters under a research license agreement (personal communication from R. Hovorka). In addition, all subjects identified to date using the Medtronic Virtual Patient (MVP) model are now publicly available, 4 but this only includes 10 adult subjects studied under that company's closed-loop controller. 25 Similarly, a limited subset of patient parameters are available for the UVA simulator. 2 The positive outcome of this year's meeting was that all the participants expressed interest in attending a new workshop devoted to presenting and discussing their models. David Klonoff (editor-in-chief of this journal and a key individual responsible for organizing the meeting) has written an article highlighting how such a workshop might be conducted. 26 Moreover, given the interest by the GMWG participants and the subsequent positive feedback from senior leadership in distinct organizations, the U.S. Army is considering sponsoring such an event for 2011. While many of the details obviously need to be finalized, one of the key ideas being considered is to make new data available for investigators to identify (i.e., customize) their models. This would eliminate the need for any of the investigators to divulge proprietary information and still enable a limited evaluation and comparison of the individual approaches using common data sets and testing metrics. Four data sets are recommended in the article written by Klonoff. 26 Although four data sets are unlikely to have the statistical power to detect differences in closed-loop simulation results, compared with one another or with results obtained in published clinical studies, 25, [27] [28] [29] the approach should serve to delineate broad differences in how the models perform. It is also unlikely that models used for simulation can be identified from such data, as the models are typically of high order and may require glucose tracers to be identified. 1 10, 11 and the MVP model used in a similar manner but with optimization done on closed-loop control. 30 Similarly, the low-order models used for control, for example, the glucose model 31 with multiple competing insulin/meal models used to effect control in the study by Hovorka and colleagues, 29 might be evaluated using such data (as could the internal models of virtually all the proposed MPC algorithms). Finally, all modeling approaches proposed for improving the prediction of glucose values from CGM data per se could be compared, e.g., the Wiener, 30 AR, 32 and Kalman 22 approaches.
In conclusion, the survey responses obtained at the 2009 GMWG meeting indicate a lack of consensus by many of the participants on multiple issues, suggesting that the approaches to glycemic modeling and control are still fluid. The GMWG continues to look for an approach to validate and compare models, with the objective being to highlight what the strengths of the different models are and elucidate gaps and/or weaknesses. Although we cannot disagree with the desire of individual investigators to keep the details of their models confidential, the authors of this report continue to advocate open collaboration between groups as well as the need for models to undergo independent validation before being used as the sole mechanism to make control algorithms decisions or determine the underlying stability and safe operating range of a given control algorithm. With these objectives in mind, a new workshop is being planned, the U.S. Armysponsored Modeling Comparison Workshop, which will focus on comparing, contrasting, and understanding the differences among the different models and control algorithms. This workshop is planned for 2011. 
